Опубликована: Март 8, 2025
Язык: Английский
Mycoses, Год журнала: 2021, Номер 64(10), С. 1253 - 1260
Опубликована: Июль 13, 2021
Coronavirus disease (COVID-19) causes an immunosuppressed state and increases risk of secondary infections like mucormycosis. We evaluated clinical features, predisposing factors, diagnosis outcomes for mucormycosis among patients with COVID-19 infection. This prospective, observational, multi-centre study included 47 consecutive mucormycosis, diagnosed during their course illness, between January 3 March 27, 2021. Data regarding demography, underlying medical conditions, illness treatment were collected. Clinical presentations imaging biochemical characteristics outcome recorded. Of the 2567 admitted to tertiary centres, (1.8%) Mean age was 55 ± 12.8years, majority suffered from diabetes mellitus (n = 36, 76.6%). Most not vaccinated 31, 66.0%) 43, 91.5%) had developed moderate-to-severe pneumonia, while 20 (42.6%) required invasive ventilation. All received corticosteroids broad-spectrum antibiotics most 37, 78.7%) at least one anti-viral medication. time elapsed 12.1 4.6days. Eleven (23.4%) subjects succumbed disease, mostly 8, 72.7%) within 7 days diagnosis. Among who died, 10 (90.9%) pre-existing mellitus, only 2 (18.2%) just vaccine dose all requiring oxygen supplementation mechanical Mucormycosis can occur patients, especially poor glycaemic control, widespread injudicious use antibiotics, Owing high mortality, index suspicion is ensure timely appropriate in high-risk populations.
Язык: Английский
Процитировано
168
International Journal of Antimicrobial Agents, Год журнала: 2023, Номер 61(3), С. 106718 - 106718
Опубликована: Янв. 12, 2023
Invasive fungal infections (IFIs) in Asia/Pacific are a particular threat to patients with malignancies, uncontrolled diabetes mellitus or undiagnosed/untreated human immunodeficiency virus infection and acquired syndrome (HIV/AIDS). Adequate early access diagnostic tools antifungals is essential for IFI clinical management patient survival.Details on institution profile, self-perception IFI, microscopy, culture, serology, antigen detection, molecular testing, therapeutic drug monitoring were collected survey.As of June 2022, 235 centres from 40 countries/territories answered the questionnaire. More than half six countries: India (25%), China (17%), Thailand (5%), Indonesia, Iran, Japan (4% each). Candida spp. (93%) Aspergillus (75%) considered most relevant pathogens. Most institutions had microscopy (98%) culture-based approaches (97%). Furthermore, 79% 66% assays, 63% antibody tests. Access varied between countries/territories. At least one triazole was available 93% reporting sites (voriconazole [89%] common mould-active azole), whereas 80% at amphotericin B formulation, 72% echinocandin.According replies provided, resources diagnosis vary among Economical geographical factors may play key role incidence handling this disease burden. Regional cooperation be good strategy overcome shortcomings.
Язык: Английский
Процитировано
52
The Lancet Infectious Diseases, Год журнала: 2022, Номер 22(9), С. e240 - e253
Опубликована: Апрель 4, 2022
Язык: Английский
Процитировано
68
Journal of Fungi, Год журнала: 2021, Номер 7(11), С. 985 - 985
Опубликована: Ноя. 18, 2021
Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has high all-cause mortality rate and imposes significant economic, epidemiological, humanistic burden on patients healthcare system. Evidence from published epidemiological studies showed varying prevalence of COVID-19-associated mucormycosis (CAM). study aims to compute pooled CAM other associated clinical outcomes. MEDLINE, Embase, Cochrane Study Register, WHO databases were scanned retrieve relevant articles until August 2021. All reporting among eligible for inclusion. Two investigators independently screened against selection criteria, extracted data, performed quality assessment using JBI tool. The was primary outcome, diabetes, steroid exposure, outcomes interest. Comprehensive Meta-Analysis software version 2 used performing meta-analysis. meta-analysis comprised six with sample size 52,916 mean age 62.12 ± 9.69 years. duration onset 14.59 6.88 days after diagnosis. (seven cases per 1000 patients) 50 times higher than highest recorded background (0.14 patients). A found 29.6% (95% CI: 17.2-45.9%). Optimal glycemic control judicious use steroids should be approach tackling rising cases.
Язык: Английский
Процитировано
67
Plant Biotechnology Reports, Год журнала: 2023, Номер 17(4), С. 427 - 457
Опубликована: Март 14, 2023
Язык: Английский
Процитировано
31
The Lancet Regional Health - Europe, Год журнала: 2024, Номер 45, С. 101010 - 101010
Опубликована: Авг. 7, 2024
Язык: Английский
Процитировано
10
Mycoses, Год журнала: 2021, Номер 65(1), С. 103 - 109
Опубликована: Окт. 20, 2021
Most COVID-19-associated mucormycosis (CAM) cases are reported from India and neighbouring countries. Anecdotally Europe have been presented.To estimate the disease burden describe clinical presentation of CAM in Germany.We identified through German mycology networks scientific societies, collected anonymised information via FungiScope®.We 13 six tertiary referral hospitals diagnosed between March 2020 June 2021. Twelve patients had severe or critical COVID-19, eleven were mechanically ventilated for a median 8 days (range 1-27 days) before diagnosis CAM. Eleven received systemic corticosteroids. Additional underlying medical conditions all but one patient, five immunocompromised because malignancy organ transplantation, three diabetic. developed pneumonia. Mortality was 53.8% with time to death 9 0-214 despite treatment liposomal amphotericin B and/or isavuconazole 10 cases. prevalence amongst hospitalised COVID-19 overall (0.67% 0.58% two centres) those admitted intensive care unit (ICU) (1.47%, 1.78% 0.15% significantly higher compared non-COVID-19 (P < .001 respective comparisons).COVID-19-associated is rare Germany, mostly comorbidities impaired immune system treated ICU high mortality mainly rhino-orbito-cerebral mild India. Risk than other patients.
Язык: Английский
Процитировано
51
Journal of Hospital Infection, Год журнала: 2022, Номер 122, С. 173 - 179
Опубликована: Фев. 3, 2022
Язык: Английский
Процитировано
35
Mycopathologia, Год журнала: 2022, Номер 187(2-3), С. 271 - 289
Опубликована: Март 21, 2022
Язык: Английский
Процитировано
31
Current Fungal Infection Reports, Год журнала: 2022, Номер 16(4), С. 206 - 220
Опубликована: Сен. 29, 2022
Язык: Английский
Процитировано
31